Literature DB >> 2433308

Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin.

S D Berkowitz, J Dent, J Roberts, Y Fujimura, E F Plow, K Titani, Z M Ruggeri, T S Zimmerman.   

Abstract

A small but consistent proportion of the von Willebrand factor (vWF) in normal plasma is composed of 189, 176, and 140 kD fragments cleaved from the 225 kD subunit. A monoclonal antibody map of vWF, based on the reactivity of individual antibodies with cyanogen bromide and tryptic fragments of known carboxy and/or amino termini, showed that in normal and IIA von Willebrand disease (vWD) plasmas the 140 kD fragment was derived from the amino-terminal region, whereas the 176 kD fragment was derived from the carboxy-terminal region of the subunit. In type IIA vWD, however, the fragments comprised a greater proportion of circulating vWF. In contrast, plasmin cleaved a 176 kD fragment from the amino terminus and a 145 kD fragment from the carboxy terminus of the subunit. Species similar to these plasmin-cleaved fragments were demonstrated in plasmas from four patients treated with fibrinolytic agents, but not in IIA vWD.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2433308      PMCID: PMC424117          DOI: 10.1172/JCI112843

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  16 in total

1.  Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure.

Authors:  M E Switzer; P A McKee
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

2.  Two-dimensional gel analysis of soluble proteins. Charaterization of guinea pig exocrine pancreatic proteins.

Authors:  G A Scheele
Journal:  J Biol Chem       Date:  1975-07-25       Impact factor: 5.157

3.  Proteolytic cleavage of human von Willebrand factor induced by enzyme(s) released from polymorphonuclear cells.

Authors:  E A Thompson; M A Howard
Journal:  Blood       Date:  1986-05       Impact factor: 22.113

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Plasminogen: purification from human plasma by affinity chromatography.

Authors:  D G Deutsch; E T Mertz
Journal:  Science       Date:  1970-12-04       Impact factor: 47.728

6.  Methods for the production of clinically effective intermediate- and high-purity factor-VIII concentrates.

Authors:  J Newman; A J Johnson; M H Karpatkin; S Puszkin
Journal:  Br J Haematol       Date:  1971-07       Impact factor: 6.998

7.  Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody.

Authors:  C A Fulcher; T S Zimmerman
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

8.  A dot-immunobinding assay for monoclonal and other antibodies.

Authors:  R Hawkes; E Niday; J Gordon
Journal:  Anal Biochem       Date:  1982-01-01       Impact factor: 3.365

9.  Platelets have more than one binding site for von Willebrand factor.

Authors:  Z M Ruggeri; L De Marco; L Gatti; R Bader; R R Montgomery
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

10.  Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE).

Authors:  T S Zimmerman; J A Dent; Z M Ruggeri; L H Nannini
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

View more
  13 in total

1.  Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood.

Authors:  Roberta Donadelli; Jennifer N Orje; Cristina Capoferri; Giuseppe Remuzzi; Zaverio M Ruggeri
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

2.  Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA.

Authors:  D Ginsburg; B A Konkle; J C Gill; R R Montgomery; P L Bockenstedt; T A Johnson; A Y Yang
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

3.  Defective dimerization of von Willebrand factor subunits due to a Cys-> Arg mutation in type IID von Willebrand disease.

Authors:  R Schneppenheim; J Brassard; S Krey; U Budde; T J Kunicki; L Holmberg; J Ware; Z M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

4.  Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absence of ristocetin. Role of platelet activation, fibrinogen, and two distinct membrane receptors.

Authors:  L De Marco; M Mazzuccato; M Grazia Del Ben; U Budde; A B Federici; A Girolami; Z M Ruggeri
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

Review 5.  Pivotal role of ADAMTS13 function in liver diseases.

Authors:  Masahito Uemura; Yoshihiro Fujimura; Saiho Ko; Masanori Matsumoto; Yoshiyuki Nakajima; Hiroshi Fukui
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

6.  Expression of abnormal von Willebrand factor by endothelial cells from a patient with type IIA von Willebrand disease.

Authors:  R B Levene; F M Booyse; J Chediak; T S Zimmerman; D M Livingston; D C Lynch
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

7.  Proteolytic processing of von Willebrand factor subunit: heterogeneity in type-IIA von Willebrand disease.

Authors:  J Batlle; J Lasierra; A F Villamor; J L Navarro; A Pardo; M Campos; B Justiça; M F López Fernández
Journal:  Ann Hematol       Date:  1994-03       Impact factor: 3.673

8.  Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit.

Authors:  J A Dent; M Galbusera; Z M Ruggeri
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

9.  Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers.

Authors:  M Furlan; R Robles; D Affolter; D Meyer; P Baillod; B Lämmle
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

10.  Different organization of von Willebrand factor oligomers in type-2A and -2B von Willebrand disease variants: effects of DDAVP infusion and protease inhibitors.

Authors:  A Casonato; E Pontara; A Bertomoro; D Dannhauser; S Secchiero; M Zaninotto; A Girolami
Journal:  Ann Hematol       Date:  1995-10       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.